Lakefront Biotherapeutics NV has a quick ratio of 30.30. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lakefront Biotherapeutics NV's Quick Ratio or its related term are showing as below:
WBO:LKFT'
s Quick Ratio Range Over the Past 10 Years
Min: 4.49 Med: 8.56 Max: 30.3
Current: 30.3
During the past 13 years, Lakefront Biotherapeutics NV's highest Quick Ratio was 30.30. The lowest was 4.49. And the median was 8.56.
WBO:LKFT's Quick Ratio is ranked better than 96.61% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs WBO:LKFT: 30.30
Lakefront Biotherapeutics NV (WBO:LKFT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lakefront Biotherapeutics NV Quick Ratio Related Terms
Lakefront Biotherapeutics NV Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:LKFT vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's Quick Ratio falls into.
Lakefront Biotherapeutics NV Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakefront Biotherapeutics NV (WBO:LKFT) has a Quick Ratio of 30.30 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lakefront Biotherapeutics NV and its competitors. This is 254% above median its historical median of 8.56. Over the past decade, Lakefront Biotherapeutics NV's Quick Ratio has ranged from 4.49 to 30.30. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #48 out of 1417 companies in the Biotechnology industry, placing it in the top 3.4%.
Is Lakefront Biotherapeutics NV's Quick Ratio too high?
Lakefront Biotherapeutics NV's current Quick Ratio of 30.30 is 254% above median its 10-year median of 8.56. Over the past 10 years, this metric has ranged from a low of 4.49 to a high of 30.30. The Biotechnology industry median Quick Ratio is 3.60. Lakefront Biotherapeutics NV's value of 30.30 is 741.7% above this industry median. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #48 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #48 out of 1417 companies for Quick Ratio. This places Lakefront Biotherapeutics NV in the top 3% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Lakefront Biotherapeutics NV's value of 30.30 is 741.7% above this benchmark. Historically, Lakefront Biotherapeutics NV's own Quick Ratio has ranged from 4.49 to 30.30 over the past decade. While the company's 10-year median is 8.56 vs. the industry median of 3.60, Lakefront Biotherapeutics NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lakefront Biotherapeutics NV's current Quick Ratio of 30.30 is 741.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lakefront Biotherapeutics NV and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakefront Biotherapeutics NV's current Quick Ratio is 30.30, which is 254% above median its own 10-year median of 8.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (WBO:LKFT) is currently considered Possible Value Trap. The stock's GF Value™ is €104.25, compared to a current price of €25.50 — trading 75.5% below its estimated fair value. The current Quick Ratio is 30.30, which is 254% above median its 10-year median of 8.56 and 741.7% above the Biotechnology industry median of 3.60. Lakefront Biotherapeutics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (WBO:LKFT), the current Quick Ratio is 30.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (WBO:LKFT) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of €25.50 is trading 75.5% below its estimated GF Value™ of €104.25.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for WBO:LKFT:
Quick Ratio: 30.30 (254% above median its 10-year median of 8.56)
GF Value™: €104.25 vs. price of €25.50 (75.5% below fair value)
Industry Position: 741.7% above the Biotechnology median (#48 of 1417)
No single metric tells the full story. See the WBO:LKFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
60GF Score
Get the complete analysis for WBO:LKFT
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:LKFT has been successfully added to your 
